Fulgent Genetics Overview
- Year Founded
-
2011

- Status
-
Public
- Employees
-
1,313

- Stock Symbol
-
FLGT

- Investments
-
8
- Share Price
-
$19.52
- (As of Tuesday Closing)
Fulgent Genetics General Information
Description
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Contact Information
Website
www.fulgentgenetics.comCorporate Office
- 4399 Santa Anita Avenue
- Suite 205
- El Monte, CA 91731
- United States
Corporate Office
- 4399 Santa Anita Avenue
- Suite 205
- El Monte, CA 91731
- United States
Fulgent Genetics Stock Performance
As of 24-Jun-2025, Fulgent Genetics’s stock price is $19.52. Its current market cap is $594M with 30.4M shares.
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$19.52 | $19.33 | $14.57 - $25.11 | $594M | 30.4M | 341K | -$1.33 |
Fulgent Genetics Financials Summary
As of 31-Mar-2025, Fulgent Genetics has a trailing 12-month revenue of $292M.
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
---|---|---|---|---|
EV | 267,924 | 357,370 | 394,916 | 353,872 |
Revenue | 292,448 | 283,470 | 289,213 | 618,968 |
EBITDA | (33,011) | (58,502) | (169,066) | 212,076 |
Net Income | (40,776) | (42,708) | (167,825) | 143,403 |
Total Assets | 1,205,744 | 1,219,964 | 1,235,328 | 1,386,053 |
Total Debt | 7,657 | 8,468 | 15,251 | 38,937 |
Fulgent Genetics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Fulgent Genetics Comparisons
Industry
Financing
Details
Fulgent Genetics Competitors (18)
One of Fulgent Genetics’s 18 competitors is Eurofins Scientific, a Corporation company based in Luxembourg, Luxembourg.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Eurofins Scientific | Corporation | Luxembourg, Luxembourg | ||||
Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA | ||||
Crown Bioscience | Formerly VC-backed | San Diego, CA | ||||
Quest Diagnostics | Corporation | Secaucus, NJ | ||||
NeoGenomics Laboratories | Corporation | Fort Myers, FL |
Fulgent Genetics Patents
Fulgent Genetics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20250108106-A1 | Nanoencapsulated pharmaceutical composition and use thereof | Pending | 14-Mar-2022 | ||
US-20240002383-A1 | Compounds and their use as vaccine adjuvants | Pending | 24-May-2021 | ||
US-20240132493-A1 | Imidazopyridine derivatives as sting agonists | Pending | 24-May-2021 | ||
US-20240016754-A1 | Pharmaceutical composition containing taxane nanoaggregates and use thereof | Pending | 15-Feb-2021 | ||
AU-2018217318-A1 | Nanoparticles containing a taxane and their use | Inactive | 05-Feb-2013 | A61K9/5146 |
Fulgent Genetics Signals
Fulgent Genetics Investments & Acquisitions (8)
Fulgent Genetics’s most recent deal was a Merger/Acquisition with Fulgent Pharma for . The deal was made on 07-Nov-2022.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Fulgent Pharma | 07-Nov-2022 | Merger/Acquisition | Drug Discovery | ||
Inform Diagnostics | 18-Apr-2022 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
Spatial Genomics | 18-Feb-2022 | Early Stage VC | Discovery Tools (Healthcare) | ||
LAMH | 11-Sep-2021 | Later Stage VC | Laboratory Services (Healthcare) | ||
CSI Laboratories | 09-Aug-2021 | Merger/Acquisition | Laboratory Services (Healthcare) |
Fulgent Genetics ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
17.34 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile

Healthcare
Industry
of 564
Rank
Percentile

Medical Services
Subindustry
of 93
Rank
Percentile

Fulgent Genetics Exits (1)
Fulgent Genetics’s most recent exit was on 07-Nov-2022 from Fulgent Pharma. The exit was categorized as .
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Fulgent Pharma | 07-Nov-2022 | Completed |
|
Fulgent Genetics Affiliates
Subsidiaries (2)
Name | Industry | Location | Year Founded |
---|---|---|---|
Fulgent Pharma | El Monte, CA | 2016 | |
CSI Laboratories | Alpharetta, GA | 1997 |
Fulgent Genetics FAQs
-
When was Fulgent Genetics founded?
Fulgent Genetics was founded in 2011.
-
Where is Fulgent Genetics headquartered?
Fulgent Genetics is headquartered in El Monte, CA.
-
What is the size of Fulgent Genetics?
Fulgent Genetics has 1,313 total employees.
-
What industry is Fulgent Genetics in?
Fulgent Genetics’s primary industry is Other Healthcare Services.
-
Is Fulgent Genetics a private or public company?
Fulgent Genetics is a Public company.
-
What is Fulgent Genetics’s stock symbol?
The ticker symbol for Fulgent Genetics is FLGT.
-
What is the current stock price of Fulgent Genetics?
As of 24-Jun-2025 the stock price of Fulgent Genetics is $19.52.
-
What is the current market cap of Fulgent Genetics?
The current market capitalization of Fulgent Genetics is $594M.
-
What is Fulgent Genetics’s current revenue?
The trailing twelve month revenue for Fulgent Genetics is $292M.
-
Who are Fulgent Genetics’s competitors?
Eurofins Scientific, Charles River Laboratories International, Crown Bioscience, Quest Diagnostics, and NeoGenomics Laboratories are some of the 18 competitors of Fulgent Genetics.
-
What is Fulgent Genetics’s annual earnings per share (EPS)?
Fulgent Genetics’s EPS for 12 months was -$1.33.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »